Autres langues AstraZeneca PLC NYSE

Actions

AZN

US0463531089

Produits pharmaceutiques

Marché Fermé - NYSE Autres places de cotation 22:00:02 17/07/2026			Varia. 5j.	Varia. 1 janv.
168,90 ^USD	-0,23%		-1,58%	+83,73%

17/07	Actions nordiques en Amérique du Nord - Astra Zeneca recule de 0,3 %	FW
16/07	Illumina, Inc., Formation Bio, AstraZeneca, Merck et Eli Lilly and Company élargissent l'alliance Billion Cell Atlas à de nouveaux développeurs de médicaments par IA	CI

Autres langues

17/07	WOCHENVORSCHAU/27. Juli bis 1. August (31. KW)
16/07	Illumina, Inc., Formation Bio, Astrazeneca, Merck, and Eli Lilly and Company Expand Billion Cell Atlas Alliance with New Ai Drug Developers
16/07	Molecular Partners Doses First Patients in Phase 2 Study of Biliary Tract Cancer Therapy
16/07	Keymed Biosciences Expects Return to Profit in H1
15/07	Dizal Announces Global Exclusive License Agreement with AstraZeneca for Zegfrovy
15/07	Innovent Biologics Shares Surge on Spero Deal That Could Be Worth $1.1 Billion
14/07	US FDA approves Celcuity's breast cancer drug
14/07	AstraZeneca PLC agreed to acquire worldwide rights to develop and commercialise Zegfrovy from Dizal Pharmaceutical Co., Ltd. for $1.5 billion.
14/07	UK Shares Rise as Investors Weigh Middle East Tensions; BP Gains
14/07	Where would AI lead Pharma in the long run?
14/07	Global markets live: JPMorgan, BoA, Paramount, IBM, TSMC…
14/07	Europese beurzen lager door oplopende olieprijs
14/07	AstraZeneca Licenses Zegfrovy From Dizal in Up to $1.5 Billion Deal
14/07	European Midday Briefing : Shares Fall, Oil Hits One-Month High on Middle East Tensions
14/07	AstraZeneca Enters Exclusive Global License Agreement Fornovel Oral EGFR Inhibitor Zegfrovy for Lung Cancer with Dizal Pharmaceutical
14/07	AstraZeneca buys worldwide rights to cancer drug for USD1.5 billion
14/07	Dizal Pharmaceutical Co., Ltd. Grants Astrazeneca plc Worldwide Rights to Develop and Commercialise Zegfrovy
14/07	UK Stocks-Factors to watch on July 14
14/07	BP production falls; Astra lands USD1.5 billion deal
14/07	Astrazeneca schließt exklusiven Lizenzvertrag für Lungenkrebsmittel Zegfrovy
14/07	AstraZeneca Enters Exclusive License Deal For Lung Cancer Drug Zegfrovy For Up to $1.5 Billion
14/07	AstraZeneca : enters exclusive global license agreement for novel oral EGFR inhibitor Zegfrovy for lung cancer with Dizal Pharmaceutical
14/07	AstraZeneca Signs Licensing Deal With Dizal for Lung Cancer Treatment
14/07	AstraZeneca to license lung cancer drug from China's Dizal Pharmaceutical
13/07	European Equities Traded in US as ADRs Decline